Although such implants likely would not be ready for human testing for years, creating the tissue, known as a vocal fold, and showing it was functional in dog larynges and was not rejected by a mouse model of the human immune system are significant steps, researchers said.
"We never imagined that we would see the impressive level of function that we did - and that this engineered tissue, created with actual human vocal fold cells, would have such strong potential as a therapy," said Nathan Welham, a University of Wisconsin-Madison speech language pathologist and leader of the research team.
The scientists faced a formidable task in trying to engineer a replacement tissue for the vocal cord. Such tissue must be soft and pliable enough to create waves of vibration but strong enough to withstand rapid acceleration and stress.
The researchers, including Sundaram Gunasekaran, a professor at UW-Madison, took healthy vocal cord tissue from a person who had just died and four patients who had their larynges removed for reasons other than cancer.
In about two weeks, the cells formed tissue that produced many of the same proteins as normal vocal cord cells.
"They're effectively talking to each other and producing the structural proteins that make this special tissue capable of vibration," said Brian Frey, a UW-Madison associate scientist in chemistry.
To see if the tissue could make sound, the researchers transplanted it onto larynges removed from dead dogs and attached to artificial windpipes.
When humidified air blew through the model, the tissue produced sound like the musical instrument kazoo - similar to what the human voice sounds like before it is modulated by the throat, mouth and nose, Welham said.
To see if the human body would reject such an implant, the scientists placed it in two kinds of mice - one engineered to have the larynx cell donor's immune system and one with other human immune systems.
The engineered tissue grew in the mice and was not rejected, though the it was a relatively short-term test.
The study was published in the journal Science Translational Medicine.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
